ReviewStem cell reports2026
Pluripotent stem cell lines available for use in clinical applications: A comprehensive overview.
Review in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- The challenges of choosing your pluripotent stem cell line.Stem cell reports · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last 25 years, there has been tremendous progress in human pluripotent stem cell (hPSC) technology and clinical trials testing hPSC-derived products. The development of these hPSC-derived products requires the selection of a suitable hPSC line as the starting material for product manufacturing. The bespoke development of an hPSC line for product development can require significant time and resources. Given the acceleration of clinical trials testing hPSC-derived products, there is a growing need for available clinically and commercially suitable "off-the-shelf" hPSC lines. We have identified 166 clinical hPSC lines that are currently available for licensing and distribution. This paper provides details regarding these lines that may assist developers in preliminary evaluation of lines for use in clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.